ReviewFrontiers in pharmacology2021
The Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers on Clinical Outcomes of Acute Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- What is the best dialysis regimen for severe AKI to allow kidney function recovery?Clinical kidney journal · 2026Review
- AKI as a systemic syndrome and its impact on other organ systems.Critical care (London, England) · 2026Review
- Association of ACEIs/ARBs treatment with clinical outcomes in acute kidney injury: a multicenter retrospective cohort analysis.BMC pharmacology & toxicology · 2026Article
- Azilsartan as a novel anti-ferriptotic agent via the upregulation of the Nrf2/HO-1/SLC7A11/GPX4 axis and downregulation of inflammatory pathways in folic acid-induced acute kidney injury in male mice.Toxicology reports · 2026Article
- The impacts of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on rates of acute kidney injury in hospitalized adults receiving multiple nephrotoxins.BMC nephrology · 2026Article
- Drug-specific risks of acute kidney injury associated with triple whammy therapy: a nationwide self-controlled case series study in Japan.Journal of pharmaceutical health care and sciences · 2026Article
- A State-of-the-Art Review Exploring the Cardiovascular Outcomes of Renin-Angiotensin Inhibitors in Acute Kidney Injury.Cardiorenal medicine · 2026Review
- Factors potentiating risk of higher lactate level associated with metformin therapy: a cross-sectional study in an ambulatory care setting.Therapeutic advances in endocrinology and metabolism · 2026Article
- State of the art: Renal recovery after AKI - from basic science to clinical practice.Intensive care medicine · 2025Review
- The burden of acute kidney disease: an epidemiological review and importance of follow-up care.Clinical kidney journal · 2025Review
- Article
- Advancing Community Care and Access to Follow-Up after Acute Kidney Injury Hospitalization: A Randomized Clinical Trial.Journal of the American Society of Nephrology : JASN · 2025Article
- Impact of Acute Kidney Injury, Co-Existing with and without Chronic Kidney Disease on the Short-Term Adverse Outcomes Following Atherosclerotic Cardiovascular Disease Events in Patients with Diabetes.Journal of multidisciplinary healthcare · 2025Article
- Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists.Cardiovascular diabetology · 2024Observational
- The effect of pharmacist-led medication therapy management in the multidisciplinary care of acute kidney injury survivors.Kidney research and clinical practice · 2024Article
- Unraveling Chronic Cardiovascular and Kidney Disorder through the Butterfly Effect.Diagnostics (Basel, Switzerland) · 2024Review
- From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease.International journal of molecular sciences · 2024Review
- Renal Microcirculation Injury as the Main Cause of Ischemic Acute Kidney Injury Development.Biology · 2023Review
- Antihypertensives associated adverse events: a review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations.Frontiers in pharmacology · 2023Review
- Potential of soluble (pro)renin receptor in kidney disease: can it go beyond a biomarker?American journal of physiology. Renal physiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.